Abstract

A number of point mutations have been identified in reprogrammed pluripotent stem cells such as iPSCs and ntESCs. The molecular basis for these mutations has remained elusive however, which is a considerable impediment to their potential medical application. Here we report a specific stage at which iPSC generation is not reduced in response to ionizing radiation, i.e. radio-resistance. Quite intriguingly, a G1/S cell cycle checkpoint deficiency occurs in a transient fashion at the initial stage of the genome reprogramming process. These cancer-like phenomena, i.e. a cell cycle checkpoint deficiency resulting in the accumulation of point mutations, suggest a common developmental pathway between iPSC generation and tumorigenesis. This notion is supported by the identification of specific cancer mutational signatures in these cells. We describe efficient generation of human integration-free iPSCs using erythroblast cells, which have only a small number of point mutations and INDELs, none of which are in coding regions.

Point mutations have been found in induced pluripotent stem cells (iPSCs) but when they arise is unclear. Here, the authors show that a G1/S cell cycle checkpoint deficiency transiently occurs early in genome reprogramming, suggesting a common developmental pathway between iPSC and tumorigenesis, and generate genetic burden-free human iPSCs.

Details

Title
Genetic aberrations in iPSCs are introduced by a transient G1/S cell cycle checkpoint deficiency
Author
Araki Ryoko 1 ; Hoki Yuko 1 ; Suga Tomo 1 ; Obara Chizuka 1   VIAFID ORCID Logo  ; Sunayama Misato 1 ; Imadome Kaori 1 ; Fujita Mayumi 1 ; Kamimura Satoshi 1 ; Nakamura, Miki 1 ; Wakayama Sayaka 2 ; Nagy, Andras 3   VIAFID ORCID Logo  ; Wakayama Teruhiko 2   VIAFID ORCID Logo  ; Abe, Masumi 1 

 National Institutes for Quantum and Radiological Science and Technology, Department of Basic Medical Sciences for Radiation Damages, National Institute of Radiological Sciences, Chiba, Japan (GRID:grid.482503.8) (ISNI:0000 0004 5900 003X) 
 University of Yamanashi, Advanced Biotechnology Center, Kofu, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581) 
 Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada (GRID:grid.416166.2) (ISNI:0000 0004 0473 9881) ; Monash University, Australian Regenerative Medicine Institute, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2343015666
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.